After-hours movers: Costco, Scholastic Corp, Travere Therapeutics
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Travere Therapeutics (TVTX) PT Raised to $18 at Barclays
September 30, 2024 6:13 AM EDTBarclays analyst Carter Gould raised the price target on Travere Therapeutics (NASDAQ: TVTX) to $18.00 (from $14.00) while maintaining a Overweight rating.
The analyst comments "Forthcoming FSGS updates should provide steady set of catalysts de-risking regulatory path (adding $300mn+ to U.S. peak sales potential, and... More
Evercore ISI Reiterates Outperform Rating on Costco Wholesale (COST)
September 30, 2024 5:47 AM EDTEvercore ISI analyst Greg Melich reiterated an Outperform rating and $985.00 price target on Costco Wholesale (NASDAQ: COST).
The analyst comments "Bottom Line: COST remains a core retail holding, with its membership driven business model delivering extreme value, merchandising prowess, and enhanced multichannel... More
Costco Wholesale (COST) PT Raised to $972 at BofA Securities
September 27, 2024 9:59 AM EDTBofA Securities analyst Robert Ohmes raised the price target on Costco Wholesale (NASDAQ: COST) to $972.00 (from $962.00) while maintaining a Buy rating.
The analyst comments "We reiterate Buy & expect COST to gain share in the current environment as consumers continue to adjust to... More
Travere Therapeutics (TVTX) PT Lowered to $19 at Citi
September 27, 2024 7:23 AM EDTCiti analyst Carly Kenselaar lowered the price target on Travere Therapeutics (NASDAQ: TVTX) to $19.00 (from $23.00) while maintaining a Buy rating.
The analyst comments "The enrollment pause in the Ph3 HCU trial triggered by the pegtibatinase manufacturing scale-up not meeting required specs is obviously... More
Costco Wholesale (COST) PT Raised to $755 at Roth/MKM
September 27, 2024 6:13 AM EDTRoth/MKM analyst Bill Kirk raised the price target on Costco Wholesale (NASDAQ: COST) to $755.00 (from $676.00) while maintaining a Neutral rating.
The analyst comments "Elevated valuation accentuates minor operational changes. Normally the following would not be noteworthy: a small... More
Costco Wholesale (COST) PT Raised to $880 at DA Davidson
September 27, 2024 6:09 AM EDTDA Davidson analyst Michael Baker raised the price target on Costco Wholesale (NASDAQ: COST) to $880.00 (from $780.00) while maintaining a Neutral rating.
The analyst comments "With comps already known due to monthly reports, the focus for COSTs 4Q24 report was on membership fee income (MFI) and... More
Costco Wholesale (COST) PT Raised to $995 at Goldman Sachs
September 27, 2024 6:07 AM EDTGoldman Sachs analyst Kate McShane raised the price target on Costco Wholesale (NASDAQ: COST) to $995.00 (from $876.00) while maintaining a Buy rating.
The analyst comments "COST reported F4Q EPS of $5.29, above GS/consensus (Refinitiv) of $4.87/$5.08. Total company SSS (ex-gas) of +6.9% was higher than our... More
Citi Reiterates Neutral Rating on Costco Wholesale (COST)
September 27, 2024 5:34 AM EDTCiti analyst Paul Lejeuz reiterated a Neutral rating and $800.00 price target on Costco Wholesale (NASDAQ: COST)
The analyst comments "COST reported 4Q adj EPS of $5.15 ahead of cons $5.07. Core-on-core GM (which accounts for mix shift) was +9bps (last quarter was +10bps).... More
